DATA GRAPHICS | Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
March 24, 2025 11:18 PM UTC
In this month’s obesity deal for amylin analog petrelintide, Roche paid Zealand more up front than in any other single-product deal since BioCentury began collecting deals data in 2009.
The $1.65 billion cash payment is particularly notable because it went to a European biotech, not an established pharma player. The next two largest payments were for antibody-drug conjugate deals between Astrazeneca plc (LSE:AZN;NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568), a company that traces its roots to the 19th century...